Timothy Manoni, MD
Vascular Surgery · Darien, CTNPI 1821008715
Payments from drug & device makers
What this record shows
This record is dominated by other: $29,228 of the $46,188 with a category attached, or 63.3%. Angiodynamics, Inc. accounts for 64.2% of it on its own, with 32 other manufacturers making up the rest.
Across 360 payments — averaging $128.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$30K
- Medtronic$5K
- Bard Peripheral Vascular, Inc.$4K
- Endologix LLC$1K
- Silk Road Medical, Inc.$1K
- Cook Medical LLC$988
- plus $5K from 27 others
What the payments were for
- Travel & lodging$1,3793%
- Food & beverage$15,58134%
- Other$29,22863%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 18 | $29,658 |
| Medtronic(2 entities) | 67 | $4,513 |
| Bard Peripheral Vascular, Inc. | 59 | $3,546 |
| Endologix LLC | 13 | $1,395 |
| Silk Road Medical, Inc. | 10 | $1,014 |
| Cook Medical LLC | 15 | $988 |
| Johnson & Johnson(2 entities) | 48 | $973 |
| Boston Scientific | 21 | $740 |
| Lemaitre Vascular, Inc. | 12 | $673 |
| E.r. Squibb & Sons, L.L.C. | 21 | $455 |
| Philips North America LLC | 11 | $425 |
| Inari Medical, Inc. | 7 | $380 |
| Pfizer | 23 | $379 |
| Stryker | 4 | $167 |
| Biotronik Inc. | 2 | $163 |
| Lifenet Health | 1 | $161 |
| Tactile Systems Technology Inc | 8 | $141 |
| Smith+Nephew | 5 | $95 |
| Merit Medical Systems Inc | 1 | $43 |
| Sanara Medtech Inc. | 1 | $28 |
| Covidien LP | 1 | $26 |
| Reprise Biomedical, Inc. | 1 | $25 |
| Abbott | 1 | $25 |
| W. L. Gore & Associates, Inc. | 1 | $25 |
| Cardiovascular Systems Inc. | 1 | $24 |
| Asahi Intecc USA, Inc. | 1 | $21 |
| Solventum Corporation | 1 | $19 |
| Portola Pharmaceuticals, LLC | 1 | $19 |
| Bolton Medical Inc | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Cordis US CORP. | 1 | $15 |
| Bsn Medical Inc | 1 | $12 |
| Organogenesis Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$29,228
- ENDURANT IIS$1,608
- Crosser iQ$1,156
- ENROUTE Transcarotid Neuroprotection System$1,146
- Valiant Captivia$1,116
- Alto Abdominal Stent Graft System$729
- ENROUTE Transcarotid Stent$429
- Zilver PTX$394
- ENROUTE Transcarotid Stent System$322
- ENHANCE Transcarotid Peripheral Access Kit$322
- ENROUTE 0.014 Guidewire$322
- Endurant$287
- ROSEN$255
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$240
- AFX2 Bifurcated Endograft System$191
- OptiCross 35$172
- TheraGenesis Wound Matrix$161
- Orsiro$147
- Astron; Pulsar; AstronPulsar$147
- PK Papyrus$147
How this compares
$46,188 in reported general payments places this provider in the 80th percentile of 82 vascular surgery providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 47 | $56,639 |
| EliquisApixaban | 33 | $31,637 |
| ClopidogrelClopidogrel Bisulfate | 83 | $1,098 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 30 | $582 |
| Cilostazol | 27 | $346 |
| Folic Acid | 11 | $37 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $973 | $56,63947 claims |
| PfizerEliquis | $379 | $31,63733 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 82 vascular surgery providers in Connecticut.
Other vascular surgery in Darien
- Paul GagneDarien$766K
- Jonathan BowmanDarien$53K
- Taras KucherDarien$38K
- Ben MarsanDarien$36K
- Chong LiDarien$13K
- Benjamin ChandlerDarien$8K
- Andrew LazarDarien$4K
- Uwe FischerNew London$941K
- Naiem NassiriNew Haven$348K
- Lee GoldsteinStratford$272K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.